- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00283426
Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns
An Open Clinical Feasibility Study to Evaluate Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan in Thermal Burns
The purpose of this study is to determine whether soluble beta-1,3/1,6-glucan is an effective and safe treatment of thermal burns and non-injured skin where skin grafts are harvested.
Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities improve wound healing of thermal burns and non-injured skin where skin grafts are harvested.
Panoramica dello studio
Descrizione dettagliata
In severe cases, burn patients commonly exhibit a clinical picture of systemic inflammation with a variety of manifestations ranging from the presence of tachycardia, tachypnea, fever and leukocytosis, and may progress to refractory hypotension. Shock and multiple organ system dysfunction may subsequently occur. Sepsis, caused by infection or bacteremia, is also a common occurrence and a major complication in burn patients.
After cooling the burned area, pain control is important. Local burn wound care starts with cleansing the wound followed by application of topical agents to prevent infection. Such agents may have adverse local or systemic effects and may impede on the wound healing process itself. The use of synthetic or biologic materials for wound covering is becoming increasingly popular, but most of the clinical information about efficacy of such products are anecdotal.
A primary objective in burn care is to have all wounds healed within 1 month. With longer healing periods, there is an increasing likelihood of developing hypertropic scaring and alterations in pigmentation. The development of an effective wound healing agent would therefore be highly beneficial for the suffering patient in terms of decreased healing time and improved cosmetic results.
Tipo di studio
Iscrizione
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Bergen, Norvegia, 5021
- Haukeland University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- age >= 18 years
- written informed consent
Group A - patients with thermal burns
- partial thickness burns (2nd degree) requiring non-surgical primary treatment
- primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included
or
Group B - patients with thermal burns
- non-grafted partial thickness burns (2nd degree) in patients requiring autotransplantation in the early phase
- primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included
or
Group C - patients with thermal burns
- donor site(s) on the ventral side of the body and limbs in deep partial thickness burns (2nd degree) and/or full thickness burns patients requiring autotransplantation during the first 1-3 weeks after injury
- primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included
Exclusion Criteria:
- inhalation injury to airways and lungs
- chemical or high voltage electrical burn
- pregnancy, lactation
- clinical signs or symptoms of acute infection
- any prescription or non-prescription topical medication administered within one week prior to study start
- hematological and clinical/chemical parameteres judged as unacceptable by the investigator
- donor sites with re-harvesting
- previous treatment with soluble beta-1,3/1,6-glucan
- participation in other clinical studies in the last 4 weeks
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
---|
Efficacy parameters:
|
oedema
|
bleeding
|
pain on physical contact
|
exudation
|
capillary refill
|
reepithelialization
|
rubor
|
paleness
|
infectious discharge
|
smell
|
adherence of dressing
|
time since last dressing change
|
The efficacy parameters will be recorded during regular wound procedures
|
Misure di risultato secondarie
Misura del risultato |
---|
eventi avversi
|
Safety parameters:
|
vital signs (heart rate, blood pressure, body temperature)
|
parametri di laboratorio
|
The safety parameters will be recorded daily during the first week of treatment and weekly thereafter
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Tjostolv Lund, Dr.med., Haukeland University Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SBG-1-10
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Brucia
-
Hospices Civils de LyonReclutamento
-
Konya Meram State HospitalCompletatoBurns Grado SecondoTacchino
Prove cliniche su Beta-1,3/1,6-glucano solubile
-
Biotec Pharmacon ASACompletatoMucosite oraleGermania, Regno Unito
-
Biotec Pharmacon ASACompletatoUlcera del piedeFederazione Russa
-
Imuneks Farma ilac San. Tic. A.S.TC Erciyes UniversityCompletatoSintomi del raffreddoreTacchino
-
Fakultas Kedokteran Universitas IndonesiaSconosciuto
-
University of BrawijayaPT. Sahabat Lingkungan HidupIscrizione su invito
-
Al-Azhar UniversityCompletatoParodontite aggressiva localizzata
-
Fakultas Kedokteran Universitas IndonesiaSconosciuto
-
Meiji University of Oriental MedicineKyoto Prefectural University of MedicineTerminatoCongiuntivite allergicaGiappone
-
Radboud University Medical CenterCompletatoSindromi da deficit immunologicoOlanda
-
Steno Diabetes Center CopenhagenCompletato